Karyopharm Therapeutics is a clinical-stage pharmaceutical company, based in Newton, MA, USA, focused on the discovery, development and commercialization of novel, first-in-class agents targeting nuclear transport for the treatment of cancer and other major diseases. Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a central mechanism of oncogenesis via the inhibition of exportins specifically XPO1. Selinexor, Karyopharm’s lead candidate, has been administered to patients with hematologic malignancies or solid tumors in clinical trials worldwide. Karyopharm is currently preparing for its first potential U.S. commercial launch in 2019.
Reporting to the Corporate Controller, The Director of Accounting & Reporting provides leadership and technical guidance of accounting policy development and financial reporting within the Corporate Accounting department. The individual in this role is responsible for the verbal and written communication with senior leadership and external auditors for technical accounting, reporting, and accounting policies. This individual will be heavily involved with any commercial finance activity and lead all technical accounting projects and related activities including product and license revenue recognition, inventory, COGS, stock-based compensation and oversee international accounting for our ex-U.S. subsidiaries.